Knol MJ - Search Results

1

Consent in psychiatric biobanks for pharmacogenetic research.

van der Baan FH, Bernabe RD, Bredenoord AL, Gregoor JG, Meynen G, Knol MJ, van Thiel GJ. van der Baan FH, et al. Among authors: knol mj. Int J Neuropsychopharmacol. 2013 Apr;16(3):677-82. doi: 10.1017/S146114571200048X. Epub 2012 May 21. Int J Neuropsychopharmacol. 2013. PMID: 22607776 Free article. Review.

2

Pharmacogenetics in randomized controlled trials: considerations for trial design.

van der Baan FH, Klungel OH, Egberts AC, Leufkens HG, Grobbee DE, Roes KC, Knol MJ. van der Baan FH, et al. Among authors: knol mj. Pharmacogenomics. 2011 Oct;12(10):1485-92. doi: 10.2217/pgs.11.95. Pharmacogenomics. 2011. PMID: 22008051

3

Potential of adaptive clinical trial designs in pharmacogenetic research.

van der Baan FH, Knol MJ, Klungel OH, Egberts AC, Grobbee DE, Roes KC. van der Baan FH, et al. Among authors: knol mj. Pharmacogenomics. 2012 Apr;13(5):571-8. doi: 10.2217/pgs.12.10. Pharmacogenomics. 2012. PMID: 22462749

4

Added value of pharmacogenetic testing in predicting statin response: results from the REGRESS trial.

van der Baan FH, Knol MJ, Maitland-van der Zee AH, Regieli JJ, van Iperen EP, Egberts AC, Klungel OH, Grobbee DE, Jukema JW. van der Baan FH, et al. Among authors: knol mj. Pharmacogenomics J. 2013 Aug;13(4):318-24. doi: 10.1038/tpj.2012.12. Epub 2012 May 1. Pharmacogenomics J. 2013. PMID: 22547143 Clinical Trial.

5

Phase IV non-inferiority trials and additional claims of benefit.

Bernabe RD, Wangge G, Knol MJ, Klungel OH, van Delden JJ, de Boer A, Hoes AW, Raaijmakers JA, van Thiel GJ. Bernabe RD, et al. Among authors: knol mj. BMC Med Res Methodol. 2013 May 30;13:70. doi: 10.1186/1471-2288-13-70. BMC Med Res Methodol. 2013. PMID: 23721202 Free PMC article. Clinical Trial.

6

Optimizing trial design in pharmacogenetics research: comparing a fixed parallel group, group sequential, and adaptive selection design on sample size requirements.

Boessen R, van der Baan F, Groenwold R, Egberts A, Klungel O, Grobbee D, Knol M, Roes K. Boessen R, et al. Pharm Stat. 2013 Nov-Dec;12(6):366-74. doi: 10.1002/pst.1599. Epub 2013 Sep 23. Pharm Stat. 2013. PMID: 24214896

7

Recommendations for presenting analyses of effect modification and interaction.

Knol MJ, VanderWeele TJ. Knol MJ, et al. Int J Epidemiol. 2012 Apr;41(2):514-20. doi: 10.1093/ije/dyr218. Epub 2012 Jan 9. Int J Epidemiol. 2012. PMID: 22253321 Free PMC article.

8

Increasing trial efficiency by early reallocation of placebo nonresponders in sequential parallel comparison designs: application to antidepressant trials.

Boessen R, Knol MJ, Groenwold RH, Grobbee DE, Roes KC. Boessen R, et al. Among authors: knol mj. Clin Trials. 2012 Oct;9(5):578-87. doi: 10.1177/1740774512456454. Clin Trials. 2012. PMID: 23060319 Clinical Trial.

9

Estimating interaction on an additive scale between continuous determinants in a logistic regression model.

Knol MJ, van der Tweel I, Grobbee DE, Numans ME, Geerlings MI. Knol MJ, et al. Int J Epidemiol. 2007 Oct;36(5):1111-8. doi: 10.1093/ije/dym157. Epub 2007 Aug 27. Int J Epidemiol. 2007. PMID: 17726040

10

How to deal with measures of association: a short guide for the clinician.

Knol MJ, Algra A, Groenwold RH. Knol MJ, et al. Cerebrovasc Dis. 2012;33(2):98-103. doi: 10.1159/000334180. Epub 2011 Dec 13. Cerebrovasc Dis. 2012. PMID: 22156574 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

204 results

Search Page